Mental state: clinically important response, as defined by individual studies * · patients with schizophrenia
1 finding from 1 review
Global state: clinically important change in global state · patients with schizophrenia
1 finding from 1 review
Mental state: clinically important response in mental state BPRS score >30% change · patients with schizophrenia
Clozapine: low dose (150 mg/day to 300 mg/day) showed no clear difference in mental state: clinically important response in mental state BPRS… compared with standard dose (301 mg/day to 600 mg/day) (low certainty).
1 finding from 1 review
Functioning: clinically important change in general functioning, as defined by individual studies · patients with schizophrenia
1 finding from 1 review
Adverse effect: clinically important adverse effect (weight ‐ BMI) · patients with schizophrenia
1 finding from 1 review
Service use: time to hospitalisation · patients with schizophrenia
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
1 finding from 1 review
Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia
ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether INTERMITTENT (DRUG HOLIDAY) changes relapse: long term (+ 26 weeks) as defined in each study compared with MAINTENANCE THERAPY (very low certainty).
1 finding from 1 review
Hospital admissions · patients with schizophrenia
It is very uncertain whether INTERMITTENT (DRUG HOLIDAY) changes hospitalisation: medium term (13‐25 weeks) as defined in each study compared with MAINTENANCE THERAPY (very low certainty).
1 finding from 1 review
Global state: average score: long term (+ 26 weeks) Global Assessment Scale (GAS). Scale from: 0 to 100. · patients with schizophrenia
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Adverse effects: tardive dyskinesia: long term (+ 26 weeks) as defined in each study · patients with schizophrenia
It is very uncertain whether INTERMITTENT (DRUG HOLIDAY) changes adverse effects: tardive dyskinesia: long term (+ 26 weeks) as… compared with MAINTENANCE THERAPY (very low certainty).
1 finding from 1 review
Cost‐effectiveness · patients with schizophrenia
1 finding from 1 review
Leaving the study early/ loss to · patients with schizophrenia
It is very uncertain whether INTERMITTENT (DRUG HOLIDAY) changes leaving the study early/ loss to compared with MAINTENANCE THERAPY (very low certainty).
1 finding from 1 review
Specific behaviour ‐ agitation · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes mental state/behaviour: clinically significant agitation (2‐10 weeks) compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher leaving the study early: any reason ‐ when compared with high dose (… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to lower adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ When compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower adverse effects: EPS: unspecified ‐ Versus high dose (greater than… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review